HUA MEDICINE-B (02552) announced its interim results, with revenue increasing by 74% year-on-year to 378.9 million yuan. The independent commercialization strategy has proven effective.

HUA MEDICINE-B (02552) announced its interim results for 2026, reporting revenue of HKD 379 million, a year-on-year increase of 74.26%, with a net loss of HKD 30.195 million and a loss per share of HKD 0.03. In the first half of 2026, the company made solid progress in its commercialization-led organizational transformation, with Huatingning entering a rapid scaling phase and achieving strong sales growth. The expansion of production scale and improvement in commercial operational efficiency significantly reduced the companys net loss. In the first half of 2026, the company sold approximately 3,055,000 boxes of Huatingning, a 73% increase compared to the 1,764,000 boxes sold in the same period of 2025. The trend of rapid sales growth was further supported by the stable prices of drugs in the National Medical Insurance Drug Catalog for China in the calendar years 2026 and 2027. As the company's commercialization team and hospital coverage continued to expand, revenue increased by 74% year-on-year to HKD 378.9 million, reflecting the effectiveness of the companys self-commercialization strategy. The increase in production scale and efficiency led to a significant rise in gross margin for the period, reaching 61.8%, up from 54.2% in the same period last year.